GAM
TXG icon

Griffin Asset Management’s 10x Genomics TXG Stock Holding History

Griffin Asset Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,848
Closed -$424K – 241
2021
Q4 		$424K Sell
2,848
-763
-21% -$117K 0.05% 177
2021
Q3 		$526K Hold
3,611
– – 0.07% 169
2021
Q2 		$707K Buy
3,611
+450
+14% +$81.4K 0.09% 165
2021
Q1 		$572K Buy
3,161
+174
+6% +$30K 0.07% 165
2020
Q4 		$423K Buy
2,987
+35
+1% +$5.08K 0.06% 170
2020
Q3 		$368K Buy
+2,952
New +$310K 0.06% 165

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Griffin Asset Management's TXG Position: Q1 2022 in Review

Griffin Asset Management sold out of 10x Genomics (TXG) in Q1 2022, closing a stake of 2,848 shares — an estimated $424K sold.

Griffin Asset Management first reported a position in TXG in Q3 2020 and held it in 6 quarters. The position peaked at $707K in Q2 2021. 314 funds tracked by Wall St. Rank hold TXG as of Q1 2022.

  • Griffin Asset Management reported no remaining 10x Genomics position as of Q1 2022 after selling out during the quarter.
  • Griffin Asset Management sold 2,848 10x Genomics shares in Q1 2022, an estimated $424K.
  • Griffin Asset Management first reported a position in 10x Genomics in Q3 2020 and held it in 6 quarters.
  • Griffin Asset Management's 10x Genomics position peaked at $707K in Q2 2021.
  • 314 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2022.

Based on Griffin Asset Management's 13F filing for Q1 2022, filed 12 Apr 2022.